NASDAQ: ALHCAlignment Healthcare Inc Stock
$15.68-0.56 (-3.45%)
Updated May 20, 2025
ALHC Price
$15.68
Fair Value Price
N/A
Market Cap
$3.10B
52 Week Low
$6.92
52 Week High
$21.06
P/E
-32.67x
P/B
28.69x
P/S
1.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.00B
Earnings
-$90.63M
Gross Margin
11.6%
Operating Margin
-2.28%
Profit Margin
-3%
Debt to Equity
7.28
Operating Cash Flow
$58M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALHC Overview
Alignment Healthcare, Inc. offers a tech-enabled health care platform. It provides customized health care in the U.S. to seniors and those who need it through its Medicare advantage plans. The company also provides covered health care services to members enrolled in benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALHC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
A
ALHC
Ranked#8 of 10
Ranked#8 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $325.00 | A | |
| $63.74 | B | |
| $412.49 | B |
Be the first to know about important ALHC news, forecast changes, insider trades & much more!
ALHC News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALHC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALHC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALHC is poor value based on its book value relative to its share price (28.69x), compared to the US Healthcare Plans industry average (2.1x)
P/B vs Industry Valuation
ALHC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALHC due diligence checks available for Premium users.
Valuation
ALHC fair value
Fair Value of ALHC stock based on Discounted Cash Flow (DCF)
Price
$15.68
Fair Value
-$18.25
Undervalued by
185.92%
ALHC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALHC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-32.67x
Industry
14.33x
Market
25.56x
ALHC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
28.69x
Industry
2.1x
ALHC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALHC's financial health
Profit margin
Revenue
$926.9M
Net Income
-$9.1M
Profit Margin
-1%
ALHC's Earnings (EBIT) of -$68.52M... subscribe to Premium to read more.
Interest Coverage Financials
ALHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$895.6M
Liabilities
$786.6M
Debt to equity
7.28
ALHC's short-term assets ($774.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALHC's short-term assets ($774.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$16.6M
Investing
-$3.5M
Financing
$181.0k
ALHC's operating cash flow ($57.62M)... subscribe to Premium to read more.
Debt Coverage Financials
ALHC vs Healthcare Plan Stocks
Alignment Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.